MeiraGTx Holdings plc_April 16, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

MeiraGTx Holdings plc

(Exact name of registrant as specified in its charter)


Cayman Islands		001-38520		98-1448305
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

655 Third Avenue, Suite 1115

New York, NY 10017

(Address of principal executive offices) (Zip code)

(646) 860-7985

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Ordinary Shares, $0.00003881 par value per share	MGTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01Regulation FD Disclosure.

On April 16, 2026, MeiraGTx Holdings plc (the “Company”) issued a press release announcing 3-year data from the Company’s Phase 1 AQUAx clinical study of AAV-hAQP1 for the treatment of grade 2/3 radiation induced xerostomia, a copy of which is filed as Exhibit 99.1 and incorporated by reference into this Item 7.01.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01Other Events.

Recent Developments

On April 16, 2026, the Company announced positive 3-year data from the Company’s Phase 1 AQUAx clinical study of AAV-hAQP1 for the treatment of grade 2/3 radiation induced xerostomia.

Treatment was observed to be safe and well tolerated at each dose tested with no dose-limiting toxicity or treatment-related serious adverse events.

Results from Xerostomia Questionnaire (“XQ”)

Change from Baseline to Month 12 Maintained through Month 36

●

Unilateral: 7/12 (58%) had score improvements (decrease) ≥8 at 12 months

●

Bilateral: 9/12 (75%) had score improvements ≥8 at 12 months

●

Overall, at 12 months, 63% of participants achieved at least a 10-point improvement in XQ

●

The improvement in XQ score observed at 12 months was maintained through 36 months with 62% of participants reporting at least a 10-point improvement

Average Change from Baseline to Month 12 Maintained through Month 36

●

In unilaterally treated participants, an average 13-point improvement from baseline in XQ was seen at 12 months

●

In bilaterally treated participants, an average 21-point improvement from baseline in XQ was seen at 12 months

●

Overall, at 12 months, an average 17-point improvement from baseline was observed

●

The 17-point improvement in XQ score observed at 12 months was maintained through 36 months

Results from Unstimulated Whole Saliva Flow Rate (“UWSFR”)

Improvement from Baseline to Month 12 Maintained through Month 36

●

Overall, the UWSFR improved to an average of 0.36 mL/min at 12 months, within the normal range (0.3-0.4 mL/min)

●

The normalization in UWSFR observed at 12 months was maintained through 36 months with an average of 0.34 mL/min

-2-

The Company believes AAV‑hAQP1 represents a significant commercial opportunity as a potential first‑in‑class, disease‑modifying therapy for late, moderate‑to‑severe radiation‑induced xerostomia (RIX), a severe, lifelong condition with no effective treatments. Persistent RIX affects an estimated 165,000 patients in the United States and approximately 435,000 patients globally, with ~48,000 new cases globally across major markets. Market research incorporating our three‑year durability data demonstrated extremely strong physician enthusiasm, with approximately 78% clinician‑stated preference translating to ~52% projected usage after adjustment, alongside favorable payor perceptions and an estimated ~90% U.S. market access coverage. Based on primary market research commissioned by the Company, the Company estimates peak global annual revenue potential of approximately $3.7 billion, with a steady state estimate of approximately $3.2 billion annually in the late 2030s. In the U.S. alone, this translates to estimated peak annual revenue of approximately $2.0 billion, with a steady state of approximately $1.8 billion annually in the late 2030s. These estimates are supported by a concentrated U.S. treatment landscape enabling efficient access to a majority of eligible patients through a focused set of major treatment centers.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the number of patients with RIX, the market size for AAV-hAQP1, market access coverage, physician adoption, and potential global sales, as well as statements that include the words “expect,” “will,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “could,” “should,” “would,” “continue,” “anticipate,” “eligible” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, raise additional capital, repay our debt obligations, identify additional and develop existing product candidates, successfully execute strategic transactions or priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug or rare pediatric disease designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; the impact of pandemics, epidemics or outbreaks of infectious diseases on the status, enrollment, timing and results of our clinical trials and on our business, results of operations and financial condition; failure of early data to predict eventual outcomes; failure to obtain FDA or other regulatory approval for product candidates within expected time frames or at all; the novel nature and impact of negative public opinion of gene therapy; failure to comply with ongoing regulatory obligations; contamination or shortage of raw materials or other manufacturing issues; changes in healthcare laws; risks associated with our international operations; significant competition in the pharmaceutical and biotechnology industries; dependence on third parties; risks related to intellectual property; changes in tax policy or treatment; our ability to utilize our loss and tax credit carryforwards; litigation risks; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management’s estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.

-3-

Item 9.01Financial Statements and Exhibits

(d)Exhibits


Exhibit No.		Description
99.1		Press Release of MeiraGTx Holdings plc, dated as of April 16, 2026.
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

-4-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 16, 2026	MEIRAGTX HOLDINGS PLC

	By:	/s/ Richard Giroux
	Name:	Richard Giroux
	Title:	Chief Financial Officer and Chief Operating Officer

-5-

MeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits